4 results match your criteria: "HIV-1 Associated Acute Chronic Inflammatory Demyelinating Polyneuropathy"

Article Synopsis
  • - Guillain-Barre syndrome (GBS) is a rare autoimmune condition that typically follows an infection, leading to muscle weakness and possible paralysis, with a yearly incidence of 1 to 2 per 100,000 people. The most common form is acute inflammatory demyelinating polyneuropathy (AIDP).
  • - The study focused on four cases of patients who had pulmonary tuberculosis alongside GBS, emphasizing the need for careful diagnosis using specific criteria and ruling out other diseases through various tests such as MRIs and serological markers.
  • - Among the four patients studied, three were male and one female, all showing symptoms like weight loss, cough, and progressive limb weakness, with spinal fluid analysis confirming the typical signs
View Article and Find Full Text PDF
Article Synopsis
  • * Peripheral neuropathies associated with HIV include various disorders, with painful distal sensory polyneuropathy (DSP) being the most prevalent and clinically significant.
  • * Both HIV itself and the side effects of certain antiretroviral drugs contribute to the development of painful neuropathy, highlighting the need for more research to better understand the mechanisms involved.
View Article and Find Full Text PDF
Article Synopsis
  • Peripheral neuropathy is a common complication of HIV-1 infection, impacting patients at all stages of the disease and leading to significant morbidity and disability.
  • Distal sensory polyneuropathy (DSP) is the most prevalent type, often appearing in later stages of infection with symptoms like pain, numbness, and paresthesia.
  • Other neuropathies associated with HIV-1 include acute and chronic inflammatory demyelinating conditions, progressive polyradiculopathy due to cytomegalovirus, and mononeuropathy multiplex, each having different causes and clinical presentations.
View Article and Find Full Text PDF

Immune globulin intravenous (IGIV) is a sterile, highly purified immunoglobulin G (IgG) preparation made from pooled human plasma stabilized with glucose, maltose, glycine, sucrose, sorbitol, or albumin and is used as prophylaxis or therapy for various medical disorders. The Food and Drug Administration (FDA) first licensed IGIV in 1981 and has approved its use for six conditions: primary immunodeficiencies, immune-mediated thrombocytopenia, Kawasaki syndrome, recent bone marrow transplantation in patients aged > or =20 years, chronic B-cell lymphocytic leukemia, and pediatric human immunodeficiency virus type 1 (HIV-1) infection. In clinical practice, IGIV has been known to be used to treat 50-60 unapproved conditions, including acute lymphoblastic leukemia, adult HIV infection, multiple sclerosis, Guillain-Barré syndrome, and chronic inflammatory demyelinating polyneuropathy.

View Article and Find Full Text PDF